Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDM-105795 Phase 1 SAD in male AGA
NCT04913519Phase 1Completed
- Sponsor
- TechnoDerma Medicines Inc.
- Start
- Apr 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in androgenetic alopecia (AGA) comparing TDM-105795 with Placebo (2 arms). Primary endpoints: Incidence rate of any local and systemic AEs at 8 days, Number of subjects with presence (and severity) of local skin reactions (LSRs) at 8 days and 3 more. Started Apr 2021; status: completed.
02
Drugs
TDM-105795
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT04913519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04913519.